RxDoctor Payments Data

Gary Gray, MD

Internal Medicine · O Fallon, MONPI 1497729826

Payments from drug & device makers

$320in general payments, 2019–2025

Across 16 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$73
  • Novo Nordisk$59
  • Valencia Technologies Corporation$50
  • Amgen$39
  • Boehringer Ingelheim$33
  • Lilly USA, LLC$21
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$5016%
  • Food & beverage$27084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$320 in reported general payments places this provider in the 55th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$79,045
Medicare patients
280
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$301,738
EliquisApixaban139$130,493
JardianceEmpagliflozin56$79,447
MounjaroTirzepatide43$57,108
XareltoRivaroxaban31$35,437
TrulicityDulaglutide21$28,939
ArexvyRsvpref3 Antigen/As01e/Pf113$25,826
JanuviaSitagliptin Phosphate13$18,094
MyrbetriqMirabegron14$16,138
Repatha SureclickEvolocumab21$15,591
Breo ElliptaFluticasone/Vilanterol26$13,203
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,845
GlyxambiEmpagliflozin/Linagliptin12$7,205
SymbicortBudesonide/Formoterol Fumarate16$6,189
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$301,738186 claims
PfizerEliquis$73$130,493139 claims
Boehringer IngelheimJardiance, Glyxambi$33$86,65268 claims
Lilly USA, LLCMounjaro, Trulicity$21$86,04764 claims
GSKArexvy, Breo Ellipta$14$39,029139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →